Co-Diagnostics, Inc. (CODX)
| Market Cap | 5.26M -80.4% |
| Revenue (ttm) | 507.89K -93.1% |
| Net Income | -32.18M |
| EPS | -29.01 |
| Shares Out | 2.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,942 |
| Average Volume | 98,152 |
| Open | 2.350 |
| Previous Close | 2.350 |
| Day's Range | 2.310 - 2.390 |
| 52-Week Range | 2.200 - 46.500 |
| Beta | 1.32 |
| RSI | 27.67 |
| Earnings Date | Mar 19, 2026 |
About Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus... [Read more]
Financial Performance
In 2024, Co-Diagnostics's revenue was $3.92 million, a decrease of -42.53% compared to the previous year's $6.81 million. Losses were -$37.64 million, 6.53% more than in 2023.
Financial StatementsNews
Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecu...
Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. ...
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc....
Co-Diagnostics (CODX) Downgraded to Hold by Maxim Group Today | CODX Stock News
Co-Diagnostics (CODX) Downgraded to Hold by Maxim Group Today | CODX Stock News
Co-Diagnostics (CODX) Faces Delisting as Analyst Revises Rating
Co-Diagnostics (CODX) Faces Delisting as Analyst Revises Rating
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics announces 1-for-30 reverse stock split
Co-Diagnostics Announces Reverse Stock Split
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics (CODX) Secures Australian Patent for PCR Platform
Co-Diagnostics (CODX) Secures Australian Patent for PCR Platform
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-D...
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
SALT LAKE CITY , Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Co-Diagnostics (CODX) Validates Efficacy of Influenza and COVID-19 Detection Test
Co-Diagnostics (CODX) Validates Efficacy of Influenza and COVID-19 Detection Test
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
SALT LAKE CITY , Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq:...
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Co-Diagnostics, Inc. ( CODX) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Compa...
Co-Diagnostics Reports Third Quarter 2025 Financial Results
SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for t...
Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript
Co-Diagnostics, Inc. ( CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments November 5, 2025 11:00 AM EST Company Participants Dwight Egan - Chairman & C...
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
SALT LAKE CITY , Nov. 5, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular...
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY , Nov. 3, 2025 /PRNewswire...
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
SALT LAKE CITY , Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , Oct. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...